Skip to main content

ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, July 31, 2023 to discuss its second quarter 2023 operating results. Management will also provide a brief update on the business.

CONFERENCE CALL INFORMATION

To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  221.09
+3.14 (1.44%)
AAPL  259.58
+1.13 (0.44%)
AMD  234.99
+4.76 (2.07%)
BAC  51.76
+0.66 (1.29%)
GOOG  253.73
+1.20 (0.48%)
META  734.00
+0.59 (0.08%)
MSFT  520.56
+0.02 (0.00%)
NVDA  182.16
+1.88 (1.04%)
ORCL  280.07
+7.41 (2.72%)
TSLA  448.98
+10.01 (2.28%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.